StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.28−0.22 (-2.37%)

Close on Nov 17, 2026Market cap $596.89MP/E –Yield –

Cullinan Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cullinan Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$165.46M. For fiscal 2025 it was -$175.75M. The highest annual figure on record is -$29.77M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$175.75M–
FY2024Dec 31, 2024-$145.30M–
FY2023Dec 31, 2023-$134.28M–
FY2022Dec 31, 2022-$126.66M–
FY2021Dec 31, 2021-$43.43M–
FY2020Dec 31, 2020-$29.77M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$43.08M–
Q2 FY2026Jun 30, 2026-$38.22M–
Q1 FY2026Mar 31, 2026-$46.05M–
Q4 FY2025Dec 31, 2025-$38.11M–
Q3 FY2025Sep 30, 2025-$36.88M–
Q2 FY2025Jun 30, 2025-$57.61M–
Q1 FY2025Mar 31, 2025-$43.16M–
Q4 FY2024Dec 31, 2024-$36.63M–
Q3 FY2024Sep 30, 2024-$34.14M–
Q2 FY2024Jun 30, 2024-$36.29M–
Q1 FY2024Mar 31, 2024-$38.25M–
Q4 FY2023Dec 31, 2023-$18.13M–
Q3 FY2023Sep 30, 2023-$34.14M–
Q2 FY2023Jun 30, 2023-$31.01M–
Q1 FY2023Mar 31, 2023-$51.00M–
Q4 FY2022Dec 31, 2022-$24.98M–
Q3 FY2022Sep 30, 2022-$54.35M–
Q2 FY2022Jun 30, 2022-$25.42M–
Q1 FY2022Mar 31, 2022-$21.91M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q3 FY2021Sep 30, 2021-$10.55M–
Q2 FY2021Jun 30, 2021-$16.20M–
Q1 FY2021Mar 31, 2021-$1.52M–
Q4 FY2020Dec 31, 2020-$9.44M–
Q3 FY2020Sep 30, 2020-$9.07M–
Q2 FY2020Jun 30, 2020-$6.25M–
Q1 FY2020Mar 31, 2020-$5.02M–

More Cullinan Therapeutics figures

See a number that looks wrong?